Venoms As an Adjunctive Therapy for Parkinson’s Disease: Where are We Now and Where are We going?

References

• WHO. Ageing and health. www.who.int/news-room/fact-sheets/detail/ageing-and-health
   Google Scholar
• ChangAY , SkirbekkVF , TyrovolasS , KassebaumNJ , DielemanJL. Measuring population ageing: an analysis of the Global Burden of Disease Study 2017. Lancet Public Health4(3), e159–e167 (2019).
   PubMed Web of Science ®Google Scholar
• HouY , DanX , BabbarMet al.Ageing as a risk factor for neurodegenerative disease. Nat. Rev. Neurol.15(10), 565–581 (2019).
   PubMed Web of Science ®Google Scholar
• DorseyER , ShererT , OkunMS , BloemBR. The emerging evidence of the parkinson pandemic. J. Parkinsons. Dis.8(s1), S3–S8 (2018).
   PubMedGoogle Scholar
• PoeweW , SeppiK , TannerCMet al.Parkinson disease. Nat. Rev. Dis. Primers3, 17013 (2017).
   PubMed Web of Science ®Google Scholar
• KaliaLV , KaliaSK. alpha-Synuclein and Lewy pathology in Parkinson’s disease. Curr. Opin. Neurol.28(4), 375–381 (2015).
   PubMed Web of Science ®Google Scholar
• Troncoso-EscuderoP , ParraA , NassifM , VidalRL. Outside in: unraveling the role of neuroinflammation in the progression of Parkinson’s disease. Front. Neurol.9, 860 (2018).
   PubMed Web of Science ®Google Scholar
• LecoursC , BordeleauM , CantinL , ParentM , PaoloTD , TremblayME. Microglial implication in Parkinson’s disease: loss of beneficial physiological roles or gain of inflammatory functions?Front. Cell Neurosci.12, 282 (2018).
   PubMed Web of Science ®Google Scholar
• CaligioreD , HelmichRC , HallettMet al.Parkinson’s disease as a system-level disorder. NPJ Parkinsons. Dis.2, 16025 (2016).
   PubMed Web of Science ®Google Scholar
• DujardinK , SgambatoV. Neuropsychiatric disorders in parkinson’s disease: what do we know about the role of dopaminergic and non-dopaminergic systems?Front. Neurosci.14, 25 (2020).
   PubMed Web of Science ®Google Scholar
• AndersenMS , KarshenasA , BachFW , GazeraniP. Pain and sensory abnormalities in Parkinson’s disease an age- and gender-matched controlled pilot study. US Neuology11(1), 27–33 (2015).
   Google Scholar
• ZhuM , LiM , YeD , JiangW , LeiT , ShuK. Sensory symptoms in Parkinson’s disease: clinical features, pathophysiology and treatment. J. Neurosci. Res.94(8), 685–692 (2016).
   PubMed Web of Science ®Google Scholar
• ReedX , Bandres-CigaS , BlauwendraatC , CooksonMR. The role of monogenic genes in idiopathic Parkinson’s disease. Neurobiol. Dis.124, 230–239 (2019).
   PubMed Web of Science ®Google Scholar
• Bandres-CigaS , Diez-FairenM , KimJJ , SingletonAB. Genetics of Parkinson’s disease: an introspection of its journey towards precision medicine. Neurobiol. Dis.137, 104782 (2020).
   PubMed Web of Science ®Google Scholar
• NandipatiS , LitvanI. Environmental exposures and Parkinson’s disease. Int. J. Environ. Res. Public Health13(9), 881 (2016).
   PubMed Web of Science ®Google Scholar
• GoldmanSM. Environmental toxins and Parkinson’s disease. Annu. Rev. Pharmacol. Toxicol.54, 141–164 (2014).
   PubMed Web of Science ®Google Scholar
• BeitzJM. Parkinson’s disease: a review. Front. Biosci. (Schol. Ed.)6, 65–74 (2014).
   PubMedGoogle Scholar
• RektorovaI. Current treatment of behavioral and cognitive symptoms of Parkinson’s disease. Parkinsonism Relat. Disord.59, 65–73 (2019).
   PubMed Web of Science ®Google Scholar
• OertelW , SchulzJB. Current and experimental treatments of Parkinson disease: a guide for neuroscientists. J. Neurochem.139(Suppl. 1), 325–337 (2016).
   PubMed Web of Science ®Google Scholar
• DexterDT , JennerP. Parkinson disease: from pathology to molecular disease mechanisms. Free Radic. Biol. Med.62, 132–144 (2013).
   PubMed Web of Science ®Google Scholar
• KaliaLV , LangAE. Parkinson disease in 2015: evolving basic, pathological and clinical concepts in PD. Nat. Rev. Neurol.12(2), 65–66 (2016).
   PubMed Web of Science ®Google Scholar
• GazeraniP. Probiotics for Parkinson’s Disease. Int. J. Mol. Sci.20(17), 4121 (2019).
   PubMed Web of Science ®Google Scholar
• SantosSF , de OliveiraHL , YamadaES , NevesBC , PereiraAJr. The gut and Parkinson’s disease – a bidirectional pathway. Front. Neurol.10, 574 (2019).
   PubMedGoogle Scholar
• CharvinD , MedoriR , HauserRA , RascolO. Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat. Rev. Drug Discov.17(11), 844 (2018).
   PubMed Web of Science ®Google Scholar
• deOliveira Amaral H , Monge-FuentesV , BiolchiMayer Aet al.Animal venoms: therapeutic tools for tackling Parkinson’s disease. Drug Discov. Today24(11), 2202–2211 (2019).
   PubMed Web of Science ®Google Scholar
• de SouzaJM , GoncalvesBDC , GomezMV , VieiraLB , RibeiroFM. Animal toxins as therapeutic tools to treat neurodegenerative diseases. Front. Pharmacol.9, 145 (2018).
   PubMed Web of Science ®Google Scholar
• KingGF. Venoms as a platform for human drugs: translating toxins into therapeutics. Expert Opin. Biol. Ther.11(11), 1469–1484 (2011).
   PubMed Web of Science ®Google Scholar
• ChenN , XuS , ZhangY , WangF. Animal protein toxins: origins and therapeutic applications. Biophys. Rep.4(5), 233–242 (2018).
   PubMedGoogle Scholar
• PenningtonMW , CzerwinskiA , NortonRS. Peptide therapeutics from venom: current status and potential. Bioorg. Med. Chem.26(10), 2738–2758 (2018).
   PubMed Web of Science ®Google Scholar
• ClarkGC , CasewellNR , ElliottCTet al.Friends or foes? emerging impacts of biological toxins. Trends Biochem. Sci.44(4), 365–379 (2019).
   PubMed Web of Science ®Google Scholar
• YangX , WangY , WuC , LingEA. Animal venom peptides as a treasure trove for new therapeutics against neurodegenerative disorders. Curr. Med. Chem.26(25), 4749–4774 (2019).
   PubMed Web of Science ®Google Scholar
• RobinsonSD , UndheimEAB , UeberheideB , KingGF. Venom peptides as therapeutics: advances, challenges and the future of venom-peptide discovery. Expert Rev. Proteomics14(10), 931–939 (2017).
   PubMed Web of Science ®Google Scholar
• GazeraniP , CairnsBE. Venom-based biotoxins as potential analgesics. Expert Rev. Neurother.14(11), 1261–1274 (2014).
   PubMed Web of Science ®Google Scholar
• GazeraniP. Unfolding the hidden potential of venomics for chronic pain. Future Neurology12(3), 129–131 (2017).
   Google Scholar
• SilvaJ , Monge-FuentesV , GomesFet al.Pharmacological alternatives for the treatment of neurodegenerative disorders: wasp and bee venoms and their components as new neuroactive tools. Toxins (Basel)7(8), 3179–3209 (2015).
   PubMed Web of Science ®Google Scholar
• MorenoM , GiraltE. Three valuable peptides from bee and wasp venoms for therapeutic and biotechnological use: melittin, apamin and mastoparan. Toxins (Basel)7(4), 1126–1150 (2015).
   PubMed Web of Science ®Google Scholar
• WehbeR , FrangiehJ , RimaM , ElObeid D , SabatierJM , FajlounZ. Bee venom: overview of main compounds and bioactivities for therapeutic interests. Molecules24(16), 2997 (2019).
   PubMed Web of Science ®Google Scholar
• SonDJ , LeeJW , LeeYH , SongHS , LeeCK , HongJT. Therapeutic application of anti-arthritis, pain-releasing and anti-cancer effects of bee venom and its constituent compounds. Pharmacol. Ther.115(2), 246–270 (2007).
   PubMed Web of Science ®Google Scholar
• PuccaMB , CerniFA , OliveiraISet al.Bee updated: current knowledge on bee venom and bee envenoming therapy. Front. Immunol.10, 2090 (2019).
   PubMed Web of Science ®Google Scholar
• AwadK , AbushoukAI , AbdelKarimAH , MohammedM , NegidaA , ShalashAS. Bee venom for the treatment of Parkinson’s disease: how far is it possible?Biomed. Pharmacother.91, 295–302 (2017).
   PubMed Web of Science ®Google Scholar
• Monge-FuentesV , GomesFM , CamposGAet al.Neuroactive compounds obtained from arthropod venoms as new therapeutic platforms for the treatment of neurological disorders. J. Venom Anim. Toxins Incl. Trop. Dis.21, 31 (2015).
   PubMed Web of Science ®Google Scholar
• JiangX , GanesanP , RengarajanT , ChoiDK , ArulselvanP. Cellular phenotypes as inflammatory mediators in Parkinson’s disease: interventional targets and role of natural products. Biomed. Pharmacother.106, 1052–1062 (2018).
   PubMed Web of Science ®Google Scholar
• MoreSV , KumarH , KimIS , SongSY , ChoiDK. Cellular and molecular mediators of neuroinflammation in the pathogenesis of Parkinson’s disease. Mediators Inflamm.2013, 952375 (2013).
   PubMed Web of Science ®Google Scholar
• GeldersG , BaekelandtV , Vander Perren A. Linking neuroinflammation and neurodegeneration in Parkinson’s disease. J. Immunol. Res.2018, 4784268 (2018).
   PubMed Web of Science ®Google Scholar
• KimJI , YangEJ , LeeMSet al.Bee venom reduces neuroinflammation in the MPTP-induced model of Parkinson’s disease. Int. J. Neurosci.121(4), 209–217 (2011).
   PubMed Web of Science ®Google Scholar
• KinK , YasuharaT , KamedaM , DateI. Animal models for Parkinson’s disease research: trends in the 2000s. Int. J. Mol. Sci.20(21), 5402 (2019).
   PubMed Web of Science ®Google Scholar
• DooAR , KimST , KimSNet al.Neuroprotective effects of bee venom pharmaceutical acupuncture in acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson’s disease. Neurol. Res.32(Suppl. 1), 88–91 (2010).
   PubMedGoogle Scholar
• ChungES , KimH , LeeG , ParkS , KimH , BaeH. Neuro-protective effects of bee venom by suppression of neuroinflammatory responses in a mouse model of Parkinson’s disease: role of regulatory T cells. Brain Behav. Immun.26(8), 1322–1330 (2012).
   PubMed Web of Science ®Google Scholar
• ChungES , LeeG , LeeCet al.Bee venom phospholipase A2, a novel Foxp3+ regulatory T cell inducer, protects dopaminergic neurons by modulating neuroinflammatory responses in a mouse model of Parkinson’s disease. J. Immunol.195(10), 4853–4860 (2015).
   PubMed Web of Science ®Google Scholar
• YeM , ChungHS , LeeCet al.Bee venom phospholipase A2 ameliorates motor dysfunction and modulates microglia activation in Parkinson’s disease alpha-synuclein transgenic mice. Exp. Mol. Med.48(7), e244 (2016).
   PubMedGoogle Scholar
• ReynoldsAD , BanerjeeR , LiuJ , GendelmanHE , MosleyRL. Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson’s disease. J. Leukoc. Biol.82(5), 1083–1094 (2007).
   PubMed Web of Science ®Google Scholar
• MauriceN , DeltheilT , MelonCet al.Bee venom alleviates motor deficits and modulates the transfer of cortical information through the basal ganglia in rat models of Parkinson’s disease. PLoS ONE10(11), e0142838 (2015).
   PubMed Web of Science ®Google Scholar
• KimME , LeeJY , LeeKMet al.Neuroprotective effect of bee venom is mediated by reduced astrocyte activation in a subchronic MPTP-induced model of Parkinson’s disease. Arch Pharm. Res.39(8), 1160–1170 (2016).
   PubMed Web of Science ®Google Scholar
• Salthun-LassalleB , HirschEC , WolfartJ , RubergM , MichelPP. Rescue of mesencephalic dopaminergic neurons in culture by low-level stimulation of voltage-gated sodium channels. J. Neurosci.24(26), 5922–5930 (2004).
   PubMed Web of Science ®Google Scholar
• ToulorgeD , GuerreiroS , HildA , MaskosU , HirschEC , MichelPP. Neuroprotection of midbrain dopamine neurons by nicotine is gated by cytoplasmic Ca2+. FASEB J.25(8), 2563–2573 (2011).
   PubMed Web of Science ®Google Scholar
• AndersonDW , NeavinT , SmithJA , SchneiderJS. Neuroprotective effects of pramipexole in young and aged MPTP-treated mice. Brain Res.905(1–2), 44–53 (2001).
   PubMed Web of Science ®Google Scholar
• KhalilWK , AssafN , ElShebineySA , SalemNA. Neuroprotective effects of bee venom acupuncture therapy against rotenone-induced oxidative stress and apoptosis. Neurochem. Int.80, 79–86 (2015).
   PubMed Web of Science ®Google Scholar
• HanS , LeeK , YeoJet al.Effect of honey bee venom on microglial cells nitric oxide and tumor necrosis factor-alpha production stimulated by LPS. J. Ethnopharmacol.111(1), 176–181 (2007).
   PubMed Web of Science ®Google Scholar
• MoonDO , ParkSY , LeeKJet al.Bee venom and melittin reduce proinflammatory mediators in lipopolysaccharide-stimulated BV2 microglia. Int. Immunopharmacol.7(8), 1092–1101 (2007).
   PubMed Web of Science ®Google Scholar
• KimKH , KimM , LeeJ , JeonHN , KimSH , BaeH. Comparison of the protective effects of bee venom extracts with varying PLA2 compositions in a mouse model of Parkinson’s disease. Toxins (Basel)11(6), 358 (2019).
   PubMed Web of Science ®Google Scholar
• KimKH , LeeSY , ShinJ , HwangJT , JeonHN , BaeH. Dose-dependent neuroprotective effect of standardized bee venom phospholipase A2 against MPTP-induced Parkinson’s disease in mice. Front. Aging Neurosci.11, 80 (2019).
   PubMed Web of Science ®Google Scholar
• MirshafieyA. Venom therapy in multiple sclerosis. Neuropharmacology53(3), 353–361 (2007).
   PubMed Web of Science ®Google Scholar
• ChoSY , ShimSR , RheeHYet al.Effectiveness of acupuncture and bee venom acupuncture in idiopathic Parkinson’s disease. Parkinsonism Relat. Disord.18(8), 948–952 (2012).
   PubMed Web of Science ®Google Scholar
• DooKH , LeeJH , ChoSYet al.A prospective open-label study of combined treatment for idiopathic Parkinson’s disease using acupuncture and bee venom acupuncture as an adjunctive treatment. J. Altern. Complement. Med.21(10), 598–603 (2015).
   PubMed Web of Science ®Google Scholar
• HartmannA , MullnerJ , MeierNet al.Bee venom for the treatment of Parkinson disease – a randomized controlled clinical trial. PLoS ONE11(7), e0158235 (2016).
   PubMed Web of Science ®Google Scholar
• ChoSY , LeeYE , DooKHet al.Efficacy of combined treatment with acupuncture and bee venom acupuncture as an adjunctive treatment for Parkinson’s disease. J. Altern. Complement. Med.24(1), 25–32 (2018).
   PubMed Web of Science ®Google Scholar
• YinSM , ZhaoD , YuDQet al.Neuroprotection by scorpion venom heat resistant peptide in 6-hydroxydopamine rat model of early-stage Parkinson’s disease. Sheng Li Xue Bao66(6), 658–666 (2014).
   PubMedGoogle Scholar
• XiangY , WuQ , LiangLet al.Chlorotoxin-modified stealth liposomes encapsulating levodopa for the targeting delivery against Parkinson’s disease in the MPTP-induced mice model. J. Drug Target.20(1), 67–75 (2012).
   PubMed Web of Science ®Google Scholar
• MartinsNM , SantosNA , SartimMA , CintraAC , SampaioSV , SantosAC. A tripeptide isolated from Bothrops atrox venom has neuroprotective and neurotrophic effects on a cellular model of Parkinson’s disease. Chem. Biol. Interact.235, 10–16 (2015).
   PubMed Web of Science ®Google Scholar
• BertilssonG , PatroneC , ZachrissonOet al.Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson’s disease. J. Neurosci. Res.86(2), 326–338 (2008).
   PubMed Web of Science ®Google Scholar
• ChenS , YuSJ , LiYet al.Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson’s disease. Sci. Rep.8(1), 10722 (2018).
   PubMedGoogle Scholar
• KimS , MoonM , ParkS. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson’s disease. J. Endocrinol.202(3), 431–439 (2009).
   PubMed Web of Science ®Google Scholar
• AthaudaD , FoltynieT. The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson’s disease: mechanisms of action. Drug Discov. Today21(5), 802–818 (2016).
   PubMed Web of Science ®Google Scholar
• AthaudaD , MaclaganK , SkeneSSet al.Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet390(10103), 1664–1675 (2017).
   PubMed Web of Science ®Google Scholar
• Aviles-OlmosI , DicksonJ , KefalopoulouZet al.Exenatide and the treatment of patients with Parkinson’s disease. J. Clin. Invest.123(6), 2730–2736 (2013).
   PubMed Web of Science ®Google Scholar
• Aviles-OlmosI , DicksonJ , KefalopoulouZet al.Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson’s disease. J. Parkinsons. Dis.4(3), 337–344 (2014).
   PubMedGoogle Scholar
• XuH , AnD , YinSMet al.[The alterations of apoptosis factor Bcl-2/Bax in the early Parkinson’s disease rats and the protective effect of scorpion venom derived activity peptide]. Zhongguo Ying Yong Sheng Li Xue Za Zhi31(3), 225–229 (2015).
   PubMedGoogle Scholar
• KirikD , RosenbladC , BjorklundA. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp. Neurol.152(2), 259–277 (1998).
   PubMed Web of Science ®Google Scholar
• WangY , QinZH. Molecular and cellular mechanisms of excitotoxic neuronal death. Apoptosis15(11), 1382–1402 (2010).
   PubMed Web of Science ®Google Scholar
• HartmannA , MuellnerJ , MeierNet al.Correction: bee venom for the treatment of parkinson disease - a randomized controlled clinical trial. PLoS ONE11(9), e0162937 (2016).
   PubMed Web of Science ®Google Scholar
• JuckerM. The benefits and limitations of animal models for translational research in neurodegenerative diseases. Nat. Med.16(11), 1210–1214 (2010).
   PubMed Web of Science ®Google Scholar
• KhanKH. Gene expression in Mammalian cells and its applications. Adv. Pharm. Bull.3(2), 257–263 (2013).
   PubMedGoogle Scholar
• ChoKH , KimTH , JungWSet al.Pharmacoacupuncture for idiopathic Parkinson’s disease: a systematic review of randomized controlled trials. Evid. Based Complement. Alternat. Med.2018, 3671542 (2018).
   PubMed Web of Science ®Google Scholar
• HuangC , ZhangZ , CuiW. Marine-derived natural compounds for the treatment of Parkinson’s disease. Mar. Drugs17(4), 221 (2019).
   PubMed Web of Science ®Google Scholar
• LuoS , ZhangsunD , WuYet al.Characterization of a novel alpha-conotoxin from conus textile that selectively targets alpha6/alpha3beta2beta3 nicotinic acetylcholine receptors. J. Biol. Chem.288(2), 894–902 (2013).
   PubMed Web of Science ®Google Scholar